Cardiovascular & Gastrointestinal Innovative Medicines Unit, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK.
Bioorg Med Chem Lett. 2013 Jun 1;23(11):3175-9. doi: 10.1016/j.bmcl.2013.04.006. Epub 2013 Apr 10.
A series of conformationally restricted GPR119 agonists were prepared based around a 3,8-diazabicyclo[3.2.1]octane scaffold. Examples were found to have markedly different pharmacology in mouse and human despite similar levels of binding to the receptor. This highlights the large effects on GPCR phamacology that can result from small structural changes in the ligand, together with inter-species differences between receptors.
基于 3,8-二氮杂双环[3.2.1]辛烷骨架,我们设计合成了一系列结构受限的 GPR119 激动剂。尽管这些化合物对受体的亲和力相似,但在小鼠和人身上的药效学却有明显的差异。这凸显了配体的微小结构变化以及受体在种属间的差异对 GPCR 药效学的巨大影响。